{
    "clinical_study": {
        "@rank": "26816", 
        "arm_group": [
            {
                "arm_group_label": "Vanctictumab (OMP-18R5)", 
                "arm_group_type": "Experimental", 
                "description": "Vantictumab will be administered by intravenous (IV) infusion."
            }, 
            {
                "arm_group_label": "Nab-Paclitaxel", 
                "arm_group_type": "Experimental", 
                "description": "Nab-Paclitaxel will be administered by intravenous (IV) infusion."
            }, 
            {
                "arm_group_label": "Gemcitabine", 
                "arm_group_type": "Experimental", 
                "description": "Gemcitabine will be administered by intravenous (IV) infusion."
            }
        ], 
        "brief_summary": {
            "textblock": "This is an open-label Phase 1b dose-escalation study to assess the safety, tolerability, and\n      PK of vantictumab when combined with nab-paclitaxel and gemcitabine."
        }, 
        "brief_title": "A Study of Vantictumab (OMP-18R5) in Combination With Nab-Paclitaxel and Gemcitabine in Previously Untreated Stage IV Pancreatic Cancer", 
        "completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Pancreatic Cancer", 
            "Stage IV Pancreatic Cancer"
        ], 
        "condition_browse": {
            "mesh_term": "Pancreatic Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "Once the maximum tolerated dose (MTD) or maximum administered dose (MAD) has been\n      determined, up to 10 patients may be enrolled in the cohort-expansion phase to better\n      characterize the safety, tolerability and PK of vantictumab combined with nab-paclitaxel and\n      gemcitabine. Up to approximately 34 patients may be enrolled into the study."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Signed Informed Consent Form\n\n          -  Age \u226518 years\n\n          -  Histologically documented Stage IV ductal adenocarcinoma of the pancreas\n\n          -  Availability of tumor tissue, either archival FFPE or obtained at study entry through\n             fresh biopsy\n\n          -  ECOG performance status of 0 or 1\n\n          -  Adequate hematologic and end-organ function\n\n          -  Evaluable or measurable disease per RECIST v1.1\n\n          -  For women of childbearing potential and men with partners of childbearing potential,\n             agreement to use two effective forms of contraception\n\n        Exclusion Criteria:\n\n          -  Prior therapy before Day 1 of Cycle 1 for the treatment of Stage IV pancreatic cancer\n\n          -  Prior adjuvant therapy for the treatment of ductal adenocarcinoma of the pancreas\n\n          -  Known hypersensitivity to any component of study treatments\n\n          -  Known brain metastases, uncontrolled seizure disorder, or active neurologic disease"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "90 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "34", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 3, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02005315", 
            "org_study_id": "18R5-003"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Vanctictumab (OMP-18R5)", 
                    "Nab-Paclitaxel", 
                    "Gemcitabine"
                ], 
                "description": "Administered intravenous (IV) infusion.", 
                "intervention_name": "Vantictumab", 
                "intervention_type": "Drug", 
                "other_name": "OMP-18R5"
            }, 
            {
                "arm_group_label": [
                    "Vanctictumab (OMP-18R5)", 
                    "Nab-Paclitaxel", 
                    "Gemcitabine"
                ], 
                "description": "Nab-Paclitaxel will be administered by intravenous (IV) infusion.", 
                "intervention_name": "Nab-Paclitaxel", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Vanctictumab (OMP-18R5)", 
                    "Nab-Paclitaxel", 
                    "Gemcitabine"
                ], 
                "description": "Gemcitabine will be administered by intravenous (IV) infusion.", 
                "intervention_name": "Gemcitabine", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Gemcitabine", 
                "Paclitaxel"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Pancreatic Cancer", 
            "Stage IV Pancreatic Cancer"
        ], 
        "lastchanged_date": "May 8, 2014", 
        "location": [
            {
                "contact": {
                    "email": "lenz@usc.edu", 
                    "last_name": "Heinz-Josef Lenz, MD", 
                    "phone": "(323) 865-3955"
                }, 
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90033"
                    }, 
                    "name": "USC/Norris Comprehensive Cancer Center"
                }, 
                "investigator": {
                    "last_name": "Heinz-Josef Lenz, M.D., F.A.C.P.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "wells.messersmith@ucdenver.edu", 
                    "last_name": "Wells A Messersmith, MD, FACP", 
                    "phone": "720-848-0300"
                }, 
                "facility": {
                    "address": {
                        "city": "Aurora", 
                        "country": "United States", 
                        "state": "Colorado", 
                        "zip": "80045"
                    }, 
                    "name": "Anschutz Cancer Pavillion"
                }, 
                "investigator": {
                    "last_name": "Wells A Messersmith, MD, FACP", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "rc2@iupui.edu", 
                    "last_name": "Romnee Clark, MD", 
                    "phone": "317-948-7576"
                }, 
                "facility": {
                    "address": {
                        "city": "Indianapolis", 
                        "country": "United States", 
                        "state": "Indiana", 
                        "zip": "46202"
                    }, 
                    "name": "Indiana University Health Hospital"
                }, 
                "investigator": {
                    "last_name": "Romnee Clark, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "shahdas@iu.edu", 
                    "last_name": "Safi Shahda, MD", 
                    "phone": "317-948-6942"
                }, 
                "facility": {
                    "address": {
                        "city": "Indianapolis", 
                        "country": "United States", 
                        "state": "Indiana", 
                        "zip": "46202"
                    }, 
                    "name": "lU Health University Hospital"
                }, 
                "investigator": {
                    "last_name": "Safi Shahda, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "steven.cohen@fccc.edu", 
                    "last_name": "Steven Cohen, M.D.", 
                    "phone": "215-728-3450"
                }, 
                "facility": {
                    "address": {
                        "city": "Philadelphia", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "19111"
                    }, 
                    "name": "Fox Chase Cancer Center"
                }, 
                "investigator": {
                    "last_name": "Steven Cohen, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "jordan.berlin@vanderbilt.edu", 
                    "last_name": "Jordan Berlin, MD", 
                    "phone": "615-343-4967"
                }, 
                "facility": {
                    "address": {
                        "city": "Nashville", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37232"
                    }, 
                    "name": "Henry-Joyce Cancer Clinic"
                }, 
                "investigator": {
                    "last_name": "Jordan Belin, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Phase 1b Dose Escalation Study of Vantictumab (OMP-18R5) in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Previously Untreated Stage IV Pancreatic Cancer", 
        "overall_official": {
            "affiliation": "Indiana University Institutional Review Board (IRB)", 
            "last_name": "Romnee Clark, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The maximum tolerated dose (MTD) will be determined in patients treated with vantictumab in combination with weekly nab-paclitaxel", 
            "measure": "Phase 1b:  Safety and tolerability of vantictumab in combination with nab-paclitaxel and gemcitabine in patients with previously untreated Stage IV pancreatic cancer", 
            "safety_issue": "Yes", 
            "time_frame": "Subjects will be treated and observed for DLT through the end of the first cycle (Days 0-28)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02005315"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Apparent half life, AUC, clearance, volume of distribution", 
            "measure": "Pharmacokinetics (PK) of vantictumab when administered in combination with nab-paclitaxel and gemcitabine to patients with previously untreated Stage IV pancreatic cancer", 
            "safety_issue": "Yes", 
            "time_frame": "Vantictumab will be administered IV on Days 1 and 15 of each 28-day cycle. Nab-paclitaxel and gemcitabine will be administered IV on Days 1, 8, and 15 of each cycle."
        }, 
        "source": "OncoMed Pharmaceuticals, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "OncoMed Pharmaceuticals, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}